These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21801234)

  • 61. Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.
    Krause G; Baki I; Kerwien S; Knödgen E; Neumann L; Göckeritz E; Landwehr T; Heider KH; Hallek M
    Br J Haematol; 2016 Jun; 173(5):791-4. PubMed ID: 26271483
    [No Abstract]   [Full Text] [Related]  

  • 62. The chronic lymphocytic leukaemia market.
    Esencay M; Hamad B
    Nat Rev Drug Discov; 2015 Jun; 14(6):381-2. PubMed ID: 25976389
    [No Abstract]   [Full Text] [Related]  

  • 63. Reversible renal failure due to specific infiltration of the kidney in chronic lymphocytic leukaemia.
    Comerma-Coma MI; Sans-Boix A; Tuset-Andújar E; Andreu-Navarro J; Pérez-Ruiz A; Naval-Marcos I
    Nephrol Dial Transplant; 1998 Jun; 13(6):1550-2. PubMed ID: 9641192
    [No Abstract]   [Full Text] [Related]  

  • 64. Breakthrough infection of Trichosporon asahii in a patient with chronic lymphocytic leukemia.
    Miura Y; Kaneko M; Nishizawa M; Okamoto K; Hirai M; Kaneko H; Watanabe M; Tsudo M
    Int J Hematol; 2007 Feb; 85(2):177-8. PubMed ID: 17322000
    [No Abstract]   [Full Text] [Related]  

  • 65. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):362-4. PubMed ID: 24472805
    [No Abstract]   [Full Text] [Related]  

  • 66. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.
    Mozas P; Rivas-Delgado A; Baumann T; Villamor N; Ortiz-Maldonado V; Aymerich M; Costa D; Navarro A; Giné E; López-Guillermo A; Montserrat E; Delgado J
    Blood Cancer J; 2018 Jan; 8(1):10. PubMed ID: 29339727
    [No Abstract]   [Full Text] [Related]  

  • 67. Antibody-drug conjugates in non-Hodgkin lymphoma.
    Lim ST
    Lancet Oncol; 2015 Jun; 16(6):607-8. PubMed ID: 25925618
    [No Abstract]   [Full Text] [Related]  

  • 68. Inter- and intraindividual differences in oral chlorambucil pharmacokinetics.
    Hartvig P; Simonsson B; Oberg G; Wallin I; Ehrsson H
    Eur J Clin Pharmacol; 1988; 35(5):551-4. PubMed ID: 3069479
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Acute transformation of chronic large granular lymphocyte leukemia into an aggressive form associated with preferential organ involvement.
    Matsubara A; Matsumoto M; Takada K; Hato T; Hasegawa H; Tamai T; Yasukawa M; Fujita S
    Acta Haematol; 1994; 91(4):206-10. PubMed ID: 7976120
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Retinal detachments due to chronic lymphocytic leukaemia.
    Murphy JA; Pitts JF; Dudgeon J; Hogg RB; Harnett AN
    Clin Lab Haematol; 1991; 13(2):217-20. PubMed ID: 1934932
    [No Abstract]   [Full Text] [Related]  

  • 71. What is your diagnosis? Chronic lymphocytic leukemia.
    Gaharan S; Gupta A; Boudreaux B; Beaufrère H
    J Avian Med Surg; 2012 Mar; 26(1):45-8. PubMed ID: 22645840
    [No Abstract]   [Full Text] [Related]  

  • 72. High levels of CD160 expression up-regulated counts of chronic lymphocytic leukemia cells and were associated with other clinical parameters in Chinese patients with chronic lymphocytic leukemia.
    Zhang ZH; Chen S; Chen S; Liu Y; Qu JH
    Leuk Lymphoma; 2015 Feb; 56(2):529-32. PubMed ID: 24882258
    [No Abstract]   [Full Text] [Related]  

  • 73. Enhancing monoclonal antibody activity in chronic lymphocytic leukemia.
    Johnston JB
    Leuk Lymphoma; 2015; 56(8):2231-2. PubMed ID: 26247301
    [No Abstract]   [Full Text] [Related]  

  • 74. Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management.
    Rossi C; Brisou G; Baseggio L; Roch J; Safar V; Karlin L; Sesques P; Bouafia-Sauvy F; Lebras L; Coiffier B; Salles G; Michallet AS
    Leuk Lymphoma; 2014 Aug; 55(8):1939-41. PubMed ID: 24237449
    [No Abstract]   [Full Text] [Related]  

  • 75. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia.
    Visentin A; Gurrieri C; Imbergamo S; Lessi F; Di Maggio SA; Frezzato F; Adami F; Zambello R; Piazza F; Semenzato G; Trentin L
    Hematol Oncol; 2017 Dec; 35(4):925-928. PubMed ID: 27641225
    [No Abstract]   [Full Text] [Related]  

  • 76. Idelalisib has CLL on the run!
    Brown JR
    Blood; 2015 Dec; 126(25):2656-7. PubMed ID: 26679541
    [No Abstract]   [Full Text] [Related]  

  • 77. Optimizing drug dosing for the treatment of chronic lymphocytic leukemia.
    Jain N
    Clin Adv Hematol Oncol; 2019 Jun; 17(6):330-331. PubMed ID: 31437134
    [No Abstract]   [Full Text] [Related]  

  • 78. FCA: forget chemoimmunotherapy with alemtuzumab?
    Hallek M
    Blood; 2012 May; 119(22):5059-60. PubMed ID: 22653949
    [No Abstract]   [Full Text] [Related]  

  • 79. Acquired epidermodysplasia verruciformis, a new opportunistic infection related to bendamustine.
    Cougoul P; Tournier E; Delavigne K; Rauzy OB; Ysebaert L; Sibaud V
    Ann Hematol; 2015 Jun; 94(6):1071-3. PubMed ID: 25677268
    [No Abstract]   [Full Text] [Related]  

  • 80. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
    Langerbeins P; Giza A; Robrecht S; Cramer P; von Tresckow J; Al-Sawaf O; Fink AM; Fürstenau M; Kater AP; van der Spek E; Niemann CU; da Cunha-Bang C; Tausch E; Schneider C; Stilgenbauer S; Fischer K; Hallek M; Eichhorst B
    Am J Hematol; 2024 Aug; 99(8):1620-1623. PubMed ID: 38757754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.